A randomized, single-center double-blinded trial on the effects of diltiazem sustained-release capsules in patients with coronary slow flow phenomenon at 6-month follow-up

Lun Li, Ye Gu, Tao Liu, Yupeng Bai, Lingbo Hou, Zhong Cheng, Liqun Hu, Bo Gao, Lun Li, Ye Gu, Tao Liu, Yupeng Bai, Lingbo Hou, Zhong Cheng, Liqun Hu, Bo Gao

Abstract

Objective: The aim of this study is to observe the chronic effects of diltiazem release capsules on patients with coronary slow flow (CSF) phenomenon.

Methods: From 2004 to 2009, 80 consecutive patients with chest pain and normal coronary arteries evidenced by coronary angiography and CSF were included in this randomized, double-blind, placebo-controlled trial. CSF patterns were evaluated by the corrected TIMI frame count. Patients were randomly assigned at 1:1 ratio to diltiazem sustained-release capsules treatment group (Dil, 90 mg twice daily) or placebo control group. Holter, liver and kidney function, treadmill exercise test, coronary angiography and left ventricular angiography were measured at baseline and after 6 months. The incidence of cardiovascular events (re-admission or progress in coronary heart disease, myocardial infarction, malignant arrhythmia or cardiac death) was evaluated during the 6 months follow up.

Results: Thirty-nine patients in control and 40 patients in Dil group completed the 6 months follow-up. There was no medication induced drug withdraw during follow up. Left ventricular ejection fraction was similar between the 2 groups at baseline and during follow up. Heart rate was significantly lower in Dil group than in control group and there was no symptomatic bradycardia and II and III degree atrioventricular conduction block in both groups. Significant improvement was observed in the onset of chest pain, treadmill exercise test and coronary blood flow in Dil group while these parameters remained unchanged in control group at the end of 6 months follow up. The incidence of cardiovascular events was similar between the two groups.

Conclusion: Diltiazem slow-release capsules improved coronary blood flow and alleviated angina in patients with CSF.

Trial registration: Chinese Clinical Trial Registry ChiCTR-TCC-11001864.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Study design flow diagram.
Figure 1. Study design flow diagram.

References

    1. Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries a new angiographic finding. Am Heart J. 1972;84:66–71.
    1. Mangieri E, Macchiarelli G, Ciavolella M, Barillà F, Avella A, et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn. 1996;37:375–381.
    1. Beltrame JF, Limaye SB, Horowitz JD. The coronary slow phenomenon:a new coronary microvascular disorder. Cardiology. 2002;97:197–202.
    1. Wang X, Geng LL, Nie SP. Coronary slow flow phenomenon: a local or systemic disease? Med Hypotheses. 2010;75:334–337.
    1. Sadamatsu K, Inoue S, Tashiro H. Coronary slow flow phenomenon caused by contrast-induced microvascular spasm. Intern Med. 2007;46:1991–1993.
    1. Fineschi M, Bravi A, Gori T. The "slow coronary flow" phenomenon: evidence of preserved coronary flow reserve despite increased resting microvascular resistances. Int J Cardiol. 2008;127:358–361.
    1. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv. 2002;57:444–451.
    1. McIvor ME, Undemir C, Lawson J, Reddinger J. Clinical effects and utility of intracoronary diltiazem. Cathet Cardiovasc Diagn. 1995;35:287–291.
    1. Sütsch G, Oechslin E, Mayer I, Hess OM. Effect of diltiazem on coronary flow reserve in patients with microvascular angina. Int J Cardiol. 1995;52:135–143.
    1. Zheng ZF, Pu XQ, Yang TL, Li CC, Peng DD, et al. Effects of intracoronary diltiazem on no-reflow phenomenon after emergent percutaneous coronary intervention in patients with acute myocardial infarction. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006;31:917–920.
    1. Gibson CM, Cannon CP, Daley WL, Dodge JT, Jr, Alexander B, Jr, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879–888.
    1. Ellestad MH. Stress Testing: Principles and Practice. Philadelphia: F A Davis Co. 1986. 526p
    1. Mangieri E, Macchiarelli G, Ciavolella M, Barillà F, Avella A, et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn. 1996;37:375–381.
    1. Beltrame JF, Hmaye SB, Wuttke RD, Horowitz JD. Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. Am Heart J. 2003;146:84–90.
    1. Shirani S, Darabian S, Jozaghi S, Hamidian R. Correlation between endothelial dysfunction in normal coronary patients with slow flow and aortic ectasia: the first report. Cardiol J. 2009;16:146–150.
    1. Mangieri E, Tanzilli G, De Vincentis G, Barillà F, Remediani S, et al. Slow coronary flow and stress myocardial perfusion imaging. Different patterns in acute patients. J Cardiovasc Med (Hagerstown) 2006;7:322–327.
    1. Rim SJ, Leong-Poi H, Lindner JR, Wei K, Fisher NG, et al. Decrease in coronary blood flow reserve during hyperlipidemia is secondary to an increase in blood viscosity. Circulation. 2001;104:2704–2709.
    1. Mangieri E, Macchiarelli G, Ciavolella M, Barillà F, Avella A, et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn. 1996;37:375–381.
    1. Konidala S, Gutterman DD. Coronary vasospasm and the regulation of coronary blood flow. Prog Cardiovasc Dis. 2004;46:349–373.
    1. Beltrame JF, Turner SP, Leslie SL, Solomon P, Freedman SB, et al. The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon. J Am Coll Cardiol. 2004;44:57–62.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다